Holen Sie sich die Stockscreener-App
68.36
0.90%
-0.62
Handel nachbörslich:
68.38
0.02
+0.03%
Schlusskurs vom Vortag:
$68.98
Offen:
$68.14
24-Stunden-Volumen:
881.58K
Relative Volume:
0.82
Marktkapitalisierung:
$1.91B
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-46.82
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
-7.14%
1M Leistung:
+79.33%
6M Leistung:
+135.04%
1J Leistung:
+8,038%
1-Tages-Spanne:
$67.00
$69.56
1-Wochen-Bereich:
$64.50
$73.88
52-Wochen-Spanne:
$0.432
$75.67
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
68.36 | 1.93B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics MS Collaboration Adds New Angle To Volatile Stock Story - simplywall.st
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet - Finviz
Nektar Therapeutics (NKTR) Price Target Increased by 13.48% to 132.45 - Nasdaq
Wall Street experts predict that Nektar (NKTR) may climb by 89.8%: Consider this information before making an investment decision - Bitget
Nektar Therapeutics to Participate in Two Investor Conferences in March - Barchart.com
Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week HighTime to Buy? - MarketBeat
Nektar Therapeutics stock hits 52-week high at 75.19 USD By Investing.com - Investing.com India
Nektar Therapeutics’ (NKTR) “Buy” Rating Reaffirmed at B. Riley Financial - Defense World
Nektar Therapeutics (NKTR) Receives Positive Analyst Rating Upgr - GuruFocus
B. Riley Securities Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration - simplywall.st
Nektar Therapeutics stock hits 52-week high at 75.19 USD - Investing.com
B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating - marketscreener.com
Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial - Medical Dialogues
Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
What is Nektar Therapeutics’s valuation compared to sectorJuly 2025 Highlights & Weekly Stock Breakout Alerts - mfd.ru
Persistent Asset Partners Ltd Takes $983,000 Position in Nektar Therapeutics $NKTR - MarketBeat
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - StreetInsider
Nektar Therapeutics stock pops on $300M equity offering - MSN
UCSF, Nektar team to test potential of antibody therapy for MS - Multiple Sclerosis News Today
Which Is a Better Investment, Liquidia Corporation or Nektar Therapeutics Stock? - AAII.com
Which Is a Better Investment, Amneal Pharmaceuticals, Inc. or Nektar Therapeutics Stock? - AAII
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
Nektar Therapeutics and UCSF explore TNFR2 agonism in MS - bioworld.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month HighShould You Buy? - MarketBeat
45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP - MarketBeat
Nektar Therapeutics Announces Research Collaboration with University of California, San Francisco - marketscreener.com
StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story”GEN - GEN - Genetic Engineering and Biotechnology News
Assessing Nektar Therapeutics (NKTR) Valuation After Positive REZOLVE AD Data And Major Equity Financing - Sahm
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis - BioSpace
Nektar Therapeutics Announces Research Collaboration With Ucsf And Dr. Stephen Hauser For Nktr-0165 - TradingView
Breakthrough Prize MS pioneer joins Nektar to test new antibody - Stock Titan
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight (2026-02-16) - Seeking Alpha
NKTR stock soars after Nektar reports positive atopic dermatitis trial results - MSN
Nektar Therapeutics prices $400M stock offering - MSN
Nektar Therapeutics closes $460 million public offering By Investing.com - Investing.com Australia
Nektar Therapeutics Secures Major Funding as Shares Rally - AD HOC NEWS
Nektar Therapeutics Announces Closing of $460 Million Public Off - GuruFocus
Nektar Therapeutics closes $460 million public offering - Investing.com
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
Nektar Therapeutics (NKTR) Is Up 88.9% After Upsized Equity Raise And Positive REZOLVE-AD DataHas The Bull Case Changed? - Sahm
Can NKTR Stock Sustain Its 1,000% Rally? - Forbes
Nektar Stock: $400M Dilution And A Make-Or-Break Phase 3 - Trefis
Nektar Therapeutics Prices Upsized Public Equity Offering - TipRanks
Nektar Therapeutics stock hits 52-week high at 66.97 USD By Investing.com - Investing.com Nigeria
Nektar Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView
Why Nektar Therapeutics (NKTR) Is Up 102.2% After Strong REZOLVE-AD Data And $400 Million Raise - Yahoo Finance
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar CEO looks to add $400 milllion for atopic dermatitis drug - The Business Journals
Nektar Therapeutics stock falls after $400 million public offering - Investing.com
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):